Roth Capital Remains Bullish on Cytori Therapeutics (CYTX) Following Q4 Results; Affirms at 'Buy'
Tweet Send to a Friend
Roth Capital reaffirmed its Buy rating and $1.50 price target on Cytori Therapeutics (Nasdaq: CYTX) following Q4 results and update ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
